Vikas Prasad

Clinical trials

• Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

  Principal investigator · Not yet recruiting · Phase 2

  Washington University School of Medicine

  2026–2028
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

  Site PI · Recruiting · Phase 1

  Novartis Pharmaceuticals

  2024–2028
• Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

  Site PI · Recruiting · Phase 2

  Convergent Therapeutics

  2024–2027
• 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

  Site PI · Recruiting · Phase 1, Phase 2

  Clarity Pharmaceuticals Ltd

  2021–2026